-
Professor Jingtao Li: Advances in Clinical Research on Traditional Chinese Medicine in the Prevention and Treatment of Liver Fibrosis
Liver fibrosis is the result of damage to the liver by pathogenic factors, leading to chronic, repeated abnormalities in liver function and the deposition of collagen and other proteins. It is a crucial factor influencing the prognosis of chronic liver disease and a necessary stage in the progression to cirrhosis. Recently, at the 25th National…
-
Professor Ailong Huang: Mechanisms of Persistent HBV Infection
Hepatitis B virus (HBV), a hepatotropic DNA virus, is the causative agent of hepatitis B. HBV-infected individuals have three types of particles in their blood: Dane particles, spherical particles, and tubular particles. The characteristics of these particles can be used to detect evidence of HBV infection through immunological methods. Recently, at the 17th National Conference…
-
EHA Expert Interview | Professor Jimin Shi: Better Pre-Transplant Treatment Options for TP53-Mutated MDS Patients: Cytoreductive or Non-Cytoreductive
Patients with TP53-mutated myelodysplastic syndromes (MDS) generally have poor prognoses and face significant treatment challenges. To improve the survival outcomes of these patients, Professor Jimin Shi’s team at The First Affiliated Hospital, Zhejiang University School of Medicine conducted an in-depth investigation into the treatment options for TP53-mutated MDS patients before transplantation. At the recent 29th…
-
EHA in 5 Minutes | Professor Linhua Yang: Latest Advances in Immune Thrombocytopenia Research (Part 1)
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by a low platelet count. At the recently held 29th European Hematology Association (EHA) Annual Meeting, significant advancements were made in the field of ITP. “Oncology Frontier – Hematology Frontier” invited Professor Linhua Yang from the Second Hospital of Shanxi Medical University to select and…
-
ASCO Five Minutes | Professor Lili Mao Interprets Highlights of Soft Tissue Sarcoma Research at the ASCO Conference
Soft tissue sarcoma (STS) is a rare and highly heterogeneous malignant tumor, and exploring treatment strategies for it has been a key focus in oncology research. In recent years, with the deepening of molecular biology and immunology research, clinical understanding and treatment methods for these diseases have continually advanced. At the recently concluded 2024 American…
-
EHA Expert Interview | Professor Bing Han: New Breakthrough in PNH Treatment – Dual-target Complement Inhibitor Shows Durable Efficacy
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and complex blood disorder with limited conventional treatment options, resulting in low survival rates and poor quality of life for patients. Innovative drugs and treatments are urgently needed to improve hemolysis control, reduce the risk of complications, and enhance survival rates and quality of life for these patients.…
-
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL
CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral infections still need to be addressed to further optimize the effectiveness of CAR-T cell therapy. At the recent 2024 European Hematology Association (EHA) Annual Meeting,…
-
Professor Xiaofan Zhu’s In-depth Analysis of EHA Selected Research on Pediatric MDS
Pediatric Myelodysplastic Syndromes (MDS) are rare hematologic disorders, with advanced MDS being particularly concerning. At the 29th Annual Meeting of the European Hematology Association (EHA 2024), Professor Xiaofan Zhu’s team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented multiple studies, including two key studies on pediatric MDS. These…
Connecting Medical Expertise through Media